We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Says Arpida Antibiotic Needs More Clinical Efficacy Data
FDA Says Arpida Antibiotic Needs More Clinical Efficacy Data
January 23, 2009
Arpida has become the latest developer of an antibiotic to treat complicated skin and skin structure infections (cSSSI) to see its NDA not approved in a complete response letter from the FDA.